Dilip Shanghvi-led Sun Pharma’s most expensive M&A deal signals fading allure of US generics business

China in particular stands out as a strategic prize. Sun’s Ganorkar called it a “$150 billion untapped opportunity” in a statement, and the acquisition provides Sun with a ready platform to participate in that growth. More generally, Sun and Organon’s complementary portfolios create cross-selling opportunities across multiple regions, especially in branded generic products, said an industry executive who asked to remain anonymous.